Table 4.

Demographics, auxology and GH treatment profile at baseline (GH initiation) and at near-adult height for all patients in GeNeSIS, the subgroup of patients in GeNeSIS who were prepubertal (Tanner stage 1) at GH start, and patients in the clinical trial, for whom NAH was attained during follow-up

	GeNeSIS		Clinical trial (n = 28)
	all (n = 90)	prepubertal (n = 42)
Female, n (%)	59 (65.6)	32 (76.2)	15 (53.6)
Age at GH initiation, years	11.0 ± 2.4 (10.5 to 11.5)	9.2 ± 2.2 (8.6 to 9.9)	9.2 ± 2.4 (8.3 to 10.2)
Age at NAH, years	15.7 ± 1.4 (15.4 to 16.o)	15.5 ± 1.3 (15.1 to 15.9)	15.5 ± 1.3 (15.0 to 16.0)
Bone age delay at baseline, years	−0.6 ± 1.5 (–1.0 to −0.2)	−0.9 ± 1.6 (–1.5 to −0.3)	−0.9 ± 0.7 (–1.2 to −0.7)
Height SDS at baseline	−3.01 ± 0.87 (–3.19 to −2.83)	−3.20 ± 0.88 (–3.48 to −2.93)	−3.20 ± 0.77 (–3.50 to −2.90)
Target height SDS	−1.14 ± 0.89 (–1.33 to −0.95)	−1.21 ± 0.77 (–1.46 to −0.97)	−1.6 ± 0.9 (–1.92 to −1.19)
NAH SDS – target height SDS	−0.96 ± 1.41 (–1.28 to −0.64)	−0.78 ± 1.21 (–1.18 to −0.38)	NA
GH dose at start, mg/kg/week	0.32 ± 0.10 (0.30 to 0.34)	0.34 ± 0.08 (0.31 to 0.37)	0.36 ± 0.02 (0.35 to 0.37)
GH dose last reported, mg/kg/week	0.33 ± 0.10 (0.30 to 0.35)	0.33 ± 0.10 (0.30 to 0.36)	0.38 ± 0.02 (0.37 to 0.38)
Treatment duration, years	4.40 ± 2.33 (3.91 to 4.90)	5.98 ± 2.15 (5.31 to 6.65)	6.02 ± 2.01 (5.24 to 6.79)

Data show mean ± SD (95% CI). CI, confidence interval; GH, growth hormone; NA, not available; NAH, near-adult height; SD, standard deviation; SDS, standard deviation score; SHOX, short stature homeobox-containing gene.